{"identifier":"/us/usc/t21/s813","title_num":"21","num":"§ 813.","heading":"Treatment of controlled substance analogues","status":null,"guid":"id92a7eb9e-1b46-11ea-8cc6-e08b531bedee","source_credit":"(Pub. L. 91–513, title II, § 203, as added Pub. L. 99–570, title I, § 1202, Oct. 27, 1986, 100 Stat. 3207–13; amended Pub. L. 100–690, title VI, § 6470(c), Nov. 18, 1988, 102 Stat. 4378; Pub. L. 115–271, title III, § 3241, Oct. 24, 2018, 132 Stat. 3950.)","seq_in_title":458,"parent_identifier":"/us/usc/t21/ch13/schI/ptB","ancestors":[{"identifier":"/us/usc/t21","level":"title","num":"Title 21—","heading":"FOOD AND DRUGS","status":null,"is_section":false},{"identifier":"/us/usc/t21/ch13","level":"chapter","num":"CHAPTER 13—","heading":"DRUG ABUSE PREVENTION AND CONTROL","status":null,"is_section":false},{"identifier":"/us/usc/t21/ch13/schI","level":"subchapter","num":"SUBCHAPTER I—","heading":"CONTROL AND ENFORCEMENT","status":null,"is_section":false},{"identifier":"/us/usc/t21/ch13/schI/ptB","level":"part","num":"Part B—","heading":"Authority To Control; Standards and Schedules","status":null,"is_section":false}],"xml":"<section xmlns=\"http://xml.house.gov/schemas/uslm/1.0\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\" xmlns:dc=\"http://purl.org/dc/elements/1.1/\" xmlns:dcterms=\"http://purl.org/dc/terms/\" style=\"-uslm-lc:I80\" id=\"id41af117a-a3d3-11e9-95d4-f3ff9237185e\" identifier=\"/us/usc/t21/s813\"><num value=\"813\">§ 813.</num><heading> Treatment of controlled substance analogues</heading><subsection style=\"-uslm-lc:I19\" class=\"indent2 firstIndent-2\" id=\"id41af117b-a3d3-11e9-95d4-f3ff9237185e\" identifier=\"/us/usc/t21/s813/a\"><num value=\"a\" class=\"bold\">(a)</num><heading class=\"bold\"> In general</heading><content><p style=\"-uslm-lc:I11\" class=\"indent0\">A controlled substance analogue shall, to the extent intended for human consumption, be treated, for the purposes of any Federal law as a controlled substance in schedule I.</p>\n</content>\n</subsection>\n<subsection style=\"-uslm-lc:I19\" class=\"indent2 firstIndent-2\" id=\"id41af117c-a3d3-11e9-95d4-f3ff9237185e\" identifier=\"/us/usc/t21/s813/b\"><num value=\"b\" class=\"bold\">(b)</num><heading class=\"bold\"> Determination</heading><chapeau>In determining whether a controlled substance analogue was intended for human consumption under subsection (a), the following factors may be considered, along with any other relevant factors:</chapeau><paragraph style=\"-uslm-lc:I12\" class=\"indent1\" id=\"id41af117d-a3d3-11e9-95d4-f3ff9237185e\" identifier=\"/us/usc/t21/s813/b/1\"><num value=\"1\">(1)</num><content> The marketing, advertising, and labeling of the substance.</content>\n</paragraph>\n<paragraph style=\"-uslm-lc:I12\" class=\"indent1\" id=\"id41af117e-a3d3-11e9-95d4-f3ff9237185e\" identifier=\"/us/usc/t21/s813/b/2\"><num value=\"2\">(2)</num><content> The known efficacy or usefulness of the substance for the marketed, advertised, or labeled purpose.</content>\n</paragraph>\n<paragraph style=\"-uslm-lc:I12\" class=\"indent1\" id=\"id41af117f-a3d3-11e9-95d4-f3ff9237185e\" identifier=\"/us/usc/t21/s813/b/3\"><num value=\"3\">(3)</num><content> The difference between the price at which the substance is sold and the price at which the substance it is purported to be or advertised as is normally sold.</content>\n</paragraph>\n<paragraph style=\"-uslm-lc:I12\" class=\"indent1\" id=\"id41af1180-a3d3-11e9-95d4-f3ff9237185e\" identifier=\"/us/usc/t21/s813/b/4\"><num value=\"4\">(4)</num><content> The diversion of the substance from legitimate channels and the clandestine importation, manufacture, or distribution of the substance.</content>\n</paragraph>\n<paragraph style=\"-uslm-lc:I12\" class=\"indent1\" id=\"id41af1181-a3d3-11e9-95d4-f3ff9237185e\" identifier=\"/us/usc/t21/s813/b/5\"><num value=\"5\">(5)</num><content> Whether the defendant knew or should have known the substance was intended to be consumed by injection, inhalation, ingestion, or any other immediate means.</content>\n</paragraph>\n<paragraph style=\"-uslm-lc:I12\" class=\"indent1\" id=\"id41af1182-a3d3-11e9-95d4-f3ff9237185e\" identifier=\"/us/usc/t21/s813/b/6\"><num value=\"6\">(6)</num><content> Any controlled substance analogue that is manufactured, formulated, sold, distributed, or marketed with the intent to avoid the provisions of existing drug laws.</content>\n</paragraph>\n</subsection>\n<subsection style=\"-uslm-lc:I19\" class=\"indent2 firstIndent-2\" id=\"id41af1183-a3d3-11e9-95d4-f3ff9237185e\" identifier=\"/us/usc/t21/s813/c\"><num value=\"c\" class=\"bold\">(c)</num><heading class=\"bold\"> Limitation</heading><content><p style=\"-uslm-lc:I11\" class=\"indent0\">For purposes of this section, evidence that a substance was not marketed, advertised, or labeled for human consumption, by itself, shall not be sufficient to establish that the substance was not intended for human consumption.</p>\n</content>\n</subsection>\n<sourceCredit id=\"id41af1184-a3d3-11e9-95d4-f3ff9237185e\">(<ref href=\"/us/pl/91/513/tII/s203\">Pub. L. 91–513, title II, § 203</ref>, as added <ref href=\"/us/pl/99/570/tI/s1202\">Pub. L. 99–570, title I, § 1202</ref>, <date date=\"1986-10-27\">Oct. 27, 1986</date>, <ref href=\"/us/stat/100/3207-13\">100 Stat. 3207–13</ref>; amended <ref href=\"/us/pl/100/690/tVI/s6470/c\">Pub. L. 100–690, title VI, § 6470(c)</ref>, <date date=\"1988-11-18\">Nov. 18, 1988</date>, <ref href=\"/us/stat/102/4378\">102 Stat. 4378</ref>; <ref href=\"/us/pl/115/271/tIII/s3241\">Pub. L. 115–271, title III, § 3241</ref>, <date date=\"2018-10-24\">Oct. 24, 2018</date>, <ref href=\"/us/stat/132/3950\">132 Stat. 3950</ref>.)</sourceCredit>\n<notes type=\"uscNote\" id=\"id41af1185-a3d3-11e9-95d4-f3ff9237185e\">\n<note style=\"-uslm-lc:I75\" topic=\"referencesInText\" id=\"id41af1186-a3d3-11e9-95d4-f3ff9237185e\">\n<heading class=\"centered smallCaps\">References in Text</heading><p style=\"-uslm-lc:I21\" class=\"indent0\">Schedule I, referred to in subsec. (a), is set out in <ref href=\"/us/usc/t21/s812/c\">section 812(c) of this title</ref>.</p>\n</note>\n<note style=\"-uslm-lc:I74\" topic=\"amendments\" id=\"id41af1187-a3d3-11e9-95d4-f3ff9237185e\"><heading class=\"centered smallCaps\">Amendments</heading><p style=\"-uslm-lc:I21\" class=\"indent0\">2018—<ref href=\"/us/pl/115/271\">Pub. L. 115–271</ref> designated existing provisions as subsec. (a), inserted heading, and added subsecs. (b) and (c).</p>\n<p style=\"-uslm-lc:I21\" class=\"indent0\">1988—<ref href=\"/us/pl/100/690\">Pub. L. 100–690</ref> substituted “any Federal law” for “this subchapter and subchapter II of this chapter”.</p>\n</note>\n</notes>\n</section>","provision":null,"duplicates":[],"release":{"label":"116-78","currency_date":"2019-12-05","congress":116,"law_num":78,"excluded_laws":[],"update_num":null,"seq":190,"is_partial":false,"caveat":null,"titles_affected":["18","21","22","28","40"],"ingested_titles":[]},"served_from":{"label":"116-78","currency_date":"2019-12-05","congress":116,"law_num":78,"excluded_laws":[],"update_num":null,"seq":190,"is_partial":false,"caveat":null,"titles_affected":["18","21","22","28","40"],"ingested_titles":[]},"content_first_seen":{"label":"116-29","currency_date":"2019-07-05","congress":116,"law_num":29,"excluded_laws":[],"update_num":null,"seq":177,"is_partial":false,"caveat":null,"titles_affected":["02","06","07","15","16","19","21","26","34","38","42","43","48","49","50"],"ingested_titles":[]},"is_exact":true,"note":null}